Archives des études
Toutes les études
Page 13 sur 52 · 1238 études
46/100
Jazz Pharmaceuticals: A Fair Price for an Unfinished Second Act
Jazz Pharmaceuticals is an Irish-domiciled specialty biopharma whose durable Xywav/Xyrem sleep franchise has funded a pivot into rare epilepsy (Epidiolex) and oncology (zanidatamab, Modeyso, Zepzelca). 2025 revenue reached $4.27 billion with $1.36 billion of operating cash flow, and Q1 2026 revenue grew 19% to $1.069 billion as the market now turns on zanidatamab's August 25, 2026 FDA decision in first-line gastric cancer and on how long Xywav can outrun Lumryz and generic competition. Rating Hold: at $238.05 the stock already prices durable Xywav defense and a timely zanidatamab step-up, leaving no meaningful margin of safety.
33/100
Uranium Energy Corp: Scarce U.S. Uranium Assets, Priced Ahead of the Proof
Uranium Energy Corp is a U.S. in-situ-recovery uranium miner running the country's only two active ISR production hubs, in Wyoming and South Texas, while building toward a domestic conversion business through its UR&C subsidiary. The balance sheet is genuinely strong, with $489.9 million in cash plus restricted cash and no debt as of April 2026, but five-year operating cash flow totaled roughly negative $192.8 million, 2025 revenue of $66.8 million still came mainly from selling purchased inventory rather than mined output, and shares outstanding rose from 378.5 million to 493.3 million since 2023. Rating Avoid: the licensed U.S. permits and policy tailwinds are real, but at $10.07 the stock already sits above even the report's optimistic per-share fair value of $9.02, leaving no margin of safety.
45/100
55Buffett
Vicor: A Real Power-Delivery Specialist, Already Priced For AI's Promise
Vicor is a specialist power-conversion supplier whose Factorized Power Architecture and modular DC-DC building blocks target the 'last-inch' power-delivery bottleneck between AI processors and the board, monetizing both product sales and a fast-growing patent-royalty stream. Full-year 2025 revenue rose 13.5% to $407.7 million with gross margin reaching 57.3% as royalty revenue grew from $15.9 million in 2023 to $57.4 million in 2025, and first-quarter 2026 backlog jumped 75% year over year to $301 million, yet the company still has not disclosed the hyperscaler customers the market assumes it serves. Rating Watch: the technical edge and momentum are real, but at a trailing P/E above 84x and zero margin of safety against the conservative scenario, the stock already prices years of unproven customer breadth.
50/100
BeOne Medicines: A Real Oncology Winner, Already Priced For More
BeOne Medicines, formerly BeiGene, is a global oncology biopharma whose economics now turn on one drug, BRUKINSA, the BTK inhibitor that outsold AstraZeneca's Calquence and AbbVie's Imbruvica in 2025 with $3.93 billion of revenue as the company crossed into sustained GAAP profitability. Full-year 2025 revenue reached $5.34 billion with $1.13 billion of operating cash flow, and first-quarter 2026 extended the trend with an 89% gross margin and raised full-year guidance, even as BRUKINSA still supplies roughly three-quarters of product revenue. Rating Hold: commercial execution and BTK leadership are real and durable, but at $303.96 the stock already prices continued BRUKINSA strength and a successful platform broadening that remains unproven, leaving no meaningful margin of safety.
37/100
42Buffett
Changzhou Juhe: Real Moat, Unproven Second Curve
Changzhou Juhe is a Shanghai STAR-listed producer of photovoltaic conductive paste whose economics turn on processing gross profit rather than headline, silver-inflated revenue. Full-year 2025 revenue reached CNY 14.59 billion but net profit barely moved to CNY 419.7 million, while operating cash flow stayed deeply negative at CNY 3.07 billion even as first-quarter 2026 gross margin jumped to a record 10.58% on stronger overseas mix. Rating Hold: execution and customer embedding are real, but at CNY 100.05 the stock already prices a margin recovery and a de-silvering transition that remain unproven, leaving no meaningful margin of safety.
43/100
Hanwei Technology: Good Technology, Bad Price
Hanwei Technology is a Shenzhen-listed industrial sensing company whose revenue now centers on smart instruments and integrated monitoring solutions rather than the stand-alone gas sensors it is still best known for, with a pending Hong Kong H-share listing adding a live capital-markets catalyst. Full-year 2025 revenue recovered 8.35% and attributable profit jumped 107.1% to CNY 158.8 million, but non-recurring-excluded profit was only CNY 38.6 million and the stock already trades around 75 times trailing earnings and 4.3 times book, well above its own CNY 16-22 ideal-buy range. Rating Avoid: the sensing technology and portfolio cleanup are real, but the price already assumes a cleaner, more proven earnings run rate than five years of weak cash conversion have delivered.
38/100
Eastman Chemical: A Cyclical Repair Story Already Priced for Stabilization
Eastman Chemical is a US specialty materials producer that has spent three decades shifting from a commodity chemical maker into a four-segment franchise, Advanced Materials, Additives & Functional Products, Chemical Intermediates, and Fibers, anchored by differentiated plastics, additives, and the Kingsport molecular-recycling platform. First-quarter 2026 revenue fell to $2.177 billion and adjusted EPS to $1.09 year over year, even as specialty volume rose more than 10 percent sequentially and 2026 capital spending is guided down to about $400 million from $546 million, improving cash conversion without requiring a demand recovery. Rating Hold: the portfolio's quality has genuinely improved and the shares yield near 5 percent, but auto, construction, and Chemical Intermediates weakness mean the current price already reflects the stabilization story, leaving little margin of safety.
44/100
ACWA Power: A Compelling National Champion Wrapped in an Undisciplined Valuation
ACWA Power is a Saudi project-finance platform, 44%-owned by sovereign wealth fund PIF, that develops and operates contracted power, desalination, and green-hydrogen assets; assets under management reached SAR 455 billion in the first quarter of 2026, even as adjusted net profit fell 34.3% year over year. The stock trades around 82x trailing earnings with 5.2x parent leverage, and even the report's optimistic SAR 170 valuation ceiling sits below the current SAR 192 price. Rating Watch: the strategic position is real, but the price has already paid for growth the business has not yet delivered.
34/100
AXT: A Real Indium Phosphide Bottleneck, Priced Well Ahead of the Business
AXT is a U.S.-listed, China-manufactured supplier of compound semiconductor substrates whose economics now hinge on indium phosphide demand from the AI optical build-out and on Chinese export-permit timing. The stock rose roughly 40-fold from its August 2025 low to today's $57.21 close on real InP backlog growth and two large equity raises, yet still trades around 35-40 times trailing sales while remaining loss-making and fully dependent on Beijing's permit cadence. Rating Avoid: the bottleneck is real, but the price already assumes a cleaner, faster payoff than the business has actually earned.
39/100
Solstice Advanced Materials: A Real Standalone Business, Not Enough Margin of Safety for the Deal
Solstice Advanced Materials is a recent Honeywell spin-off whose cash engine is refrigerants and applied solutions, now also building electronics materials and uranium-conversion businesses, and its first standalone year held up better than headline GAAP profit suggested. On July 6, 2026 the company agreed to acquire Element Solutions for about $14.5 billion in cash and stock, a deal that lifts net leverage from roughly 1.5x to 3.5x and dilutes existing holders to about 56% of the combined company, sending the stock from $82.80 down to $61.30. Rating Hold: the standalone business is genuinely solid, but today's price still does not offer enough margin of safety for both execution risk and deal risk at once.
43/100
Fervo Energy: The Geothermal Buildout Is Real, the Margin of Safety Is Not
Fervo Energy is a newly public enhanced-geothermal developer building utility-scale, contracted 24/7 power plants under its Cape Station program, still pre-commercial today with barely any revenue. The company has signed 658 MW of power purchase agreements worth about $7.2 billion in backlog and closed a $421.4 million non-recourse project-finance package, yet Q1 2026 revenue was just $61,000 against a $31.8 million net loss, and Phase II alone still needs roughly $2.2 billion more through 2028. Rating Hold: the commercial and financing progress is real, but at $27.13 the stock already sits above the conservative fair-value range, leaving essentially no margin of safety until Cape Station proves itself in operation.
37/100
China XD Electric: A Real UHV Upcycle, Priced Like It's Already Proven
China XD Electric is a central-SOE-controlled maker of UHV transmission and substation equipment, spanning switchgear, transformers and power-electronics devices, whose 2025 revenue grew 7.1% to RMB 23.76 billion and attributable net profit grew 20.5% to RMB 1.27 billion as gross margin improved 1.86 percentage points to 22.57% on a richer transformer mix. Rating Hold: order flow and margin gains are real and the balance sheet is safe, but at RMB 13.42 the stock already trades near 54 times trailing earnings on a 2025 ROE of just 5.64%, pricing in continued execution well ahead of the report's own ideal buy zone of RMB 8.0 to 9.0.
44/100
63Buffett
Sieyuan Electric: A Premium-Priced Export Compounder With Zero Margin of Safety
Sieyuan Electric is a founder-controlled Chinese power-equipment exporter whose overseas revenue reached 26.94% of 2025 sales, up 85.84% year on year, helping drive 2025 revenue growth of 39.3% to RMB 21.54 billion and net-profit growth of 53.7% to RMB 3.15 billion, even as operating cash flow of RMB 2.23 billion trailed profit and a Toshiba-related stake cut from 90% to 70% now leaks more earnings to minority holders. Rating Watch: business quality is real, but at RMB 151.73 the stock trades near 37.6 times trailing earnings, well above domestic peers Xuji, Pinggao and NARI, pricing in years of clean execution with zero margin of safety against the report's RMB 95 conservative fair value, with the ideal buy zone at RMB 78 to 88.
31/100
XJ Electric: A High-Margin HVDC Niche, But No Margin of Safety at Today's Price
XJ Electric is a state-controlled Chinese grid-equipment maker where a small HVDC converter-valve and DC control-and-protection segment, just 6.79% of 2025 revenue, delivered a 32.71% gross margin and lifted group profitability even as total 2025 revenue fell 12.27% to RMB 14.99 billion and Q1 2026 attributable profit dropped 46.50% on delivery-timing swings. Rating Hold: operating cash flow has consistently exceeded net profit and the HVDC option is real, but at RMB 20.20 the stock already sits in the acceptable-hold band with zero margin of safety against project-timing and customer-concentration risk, with the ideal buy zone at RMB 12.5 to 14.0.
32/100
Vertical Aerospace: The Aircraft Flies, the Equity Is Still Compromised
Vertical Aerospace is a pre-revenue UK developer of the piloted Valo eVTOL, pursuing concurrent CAA/EASA certification for 2028 while running on a capital structure built from optional, dilutive financing rather than cash on hand. April 2026 brought both a genuine technical breakthrough (full-scale piloted thrustborne and two-way transition flights) and an up-to-$850 million financing package whose Yorkville and Mudrick structures can hand much of the company's future value to creditors before ordinary shareholders see it. Rating Watch: the aircraft program has meaningfully de-risked, but the equity remains a high-risk claim on outcomes that financiers, not shareholders, are positioned to capture first.
39/100
EHang Holdings: China's Certified eVTOL Leader, Not Yet a Scaled Business
EHang Holdings is China's first fully certified pilotless passenger eVTOL maker, still funded by aircraft sales into tourism and demonstration use rather than a scaled urban air-mobility network. A May 2026 ASC 606 restatement cut 2025 revenue to RMB418.0 million and widened the net loss to RMB276.4 million, Q1 2026 revenue fell to just RMB25.7 million on only four deliveries, and a June 2026 Beijing light-aircraft crash that did not involve EHang still triggered a nationwide regulatory chill across the low-altitude sector. Rating Watch: certification leadership is real and cash of RMB1.03 billion buys time, but revenue-recognition and regulatory-timing risk make the shares too uncertain for new money at $5.63.
41/100
Fluence Energy: Real Storage Backlog, Not Yet Real Margins
Fluence Energy is a grid-scale battery storage systems integrator and software vendor that sells bankable project delivery and risk transfer rather than owning a battery-chemistry moat, backed by a record $5.6 billion order backlog as of March 2026 and two new hyperscaler data-center agreements. Fiscal 2025 revenue fell back to $2.26 billion, first-half fiscal 2026 gross margin was only 7.4% with free cash flow negative $285.4 million, Chinese integrators captured 76% of the global BESS market in 2025, and Fluence remains a Nasdaq-controlled company entangled in AES's pending $33.4 billion take-private sale. Rating Hold: real backlog and software optionality, but cash conversion and governance still lag the demand narrative, and at $16.74 the stock offers no margin of safety for new money.
49/100
58Buffett
Saab: Europe's Sovereign Defense Franchise Is Real, but the Margin of Safety Is Gone
Saab is Sweden's sovereign defense-systems house, supplying radar, missiles, Gripen fighters, submarines, and lifecycle support against a SEK 274 billion order backlog built on Europe's post-2022 rearmament. Q1 2026 sales grew 21% and EBIT 32%, the balance sheet stayed net-cash positive, and 72% of backlog is now international, yet the stock trades near 48x trailing earnings after a re-rating that already prices in unbooked wins like GlobalEye and further Gripen campaigns. Rating Hold: a genuine sovereign-systems compounder, but at SEK 564 the margin of safety is gone.
38/100
65Buffett
Timken: The Margin Transition Is Real, but the Price Already Assumes It's Finished
The Timken Company is a century-old US manufacturer of engineered bearings and industrial motion components, shifting from a cyclical bearings supplier toward a broader motion-and-reliability platform through two decades of adjacent acquisitions (Rollon, Cone Drive, Nadella, Bijur Delimon) and a pending sale of its lower-fit belts business to Gates. Industrial Motion's adjusted EBITDA margin expanded from 17.7% in Q1 2025 to 21.5% in Q1 2026, yet company-wide adjusted EBITDA margin was still only 17.4% in 2025 versus a 2028 target near 21-23%, and the stock has already re-rated from an average of about $74 in 2025 to $138.06, trading near 23 times 2026 adjusted EPS guidance with margin of safety near zero. Rating Hold: a genuinely improving industrial franchise, but today's price already assumes the margin transition succeeds, leaving the ideal buy zone at $100-105.
44/100
RBC Bearings: The Moat Is Real, but the Price Already Assumes the Aerospace-Defense Story Is Finished
RBC Bearings is a niche U.S. manufacturer of qualification-protected precision bearings, engineered components, and fluid-control systems for aerospace, defense, and industrial platforms, shaped over three decades by founder-CEO Michael Hartnett's 29-deal acquisition program. Fiscal 2026 revenue reached $1.87 billion as Aerospace & Defense sales grew 32.9% against 3.8% Industrial growth, backlog surged to $2.3 billion, and the stock re-rated toward premium defense-compounder multiples (about 48x adjusted EPS) even as owner-earnings yield fell near 1.8%, below the 4.27% 10-year Treasury yield. Rating Watch: an excellent, moat-protected compounder, but today's price already discounts years of successful mix conversion, leaving the ideal buy zone at $290-340.
41/100
Leonardo: A Re-Rating With Real Earnings Behind It, Priced Like the Quality Gap to BAE and Thales Is Already Closed
Leonardo S.p.A. is Italy's state-influenced aerospace and defense group, whose profit engine sits in defense electronics and helicopters and is now backed by a €56.8 billion Q1 2026 order backlog. FY2025 orders reached €23.8 billion and EBITA €1.75 billion as Europe's rearmament cycle drove a sharp re-rating, yet the stock now trades near a 30.9x trailing P/E, roughly matching cleaner peers such as Thales and BAE Systems even though Leonardo still carries a persistent state-governance discount and weaker aerostructures drag. Rating Hold: order momentum and cash generation are real, but the price already assumes much of the quality convergence that has not yet fully happened, leaving the ideal buy zone at €39-43.
31/100
X-Energy: Real Nuclear-Licensing Progress, Priced Like a Decade of Milestones Is Already Won
X-Energy is a newly IPO'd, pre-commercial advanced-nuclear reactor and fuel developer, monetizing the Xe-100 reactor design and TRISO-X fuel manufacturing through DOE cost-share funding and development-stage services rather than power sales. Rating Watch: at $18.32 the stock already discounts a meaningful share of first-of-a-kind execution success, with an ideal buy zone of $9-11 requiring either a real price pullback or bankable proof that the Seadrift project and TX-1 fuel plant convert from milestones into commercial economics.
46/100
77Buffett
Thales: A Genuine Defence-Electronics Quality Compounder, Priced Like the Best Case Is Already Locked In
Thales is a French defence-electronics and aerospace group whose 2025 sales reached €22.1 billion with free operating cash flow of €2.58 billion, now expanding into naval robotics through the Exail acquisition after absorbing Germany's F126 contract termination. Rating Hold: at €241.10 the stock already trades above its own historical average multiple, pricing in continued defence-cycle strength and a smooth Exail integration, leaving the ideal buy zone at €160-170.
46/100
Soitec: The AI-Photonics Turn Is Real, But the Price Already Assumes It Wins
Soitec designs and manufactures engineered semiconductor substrates—RF-SOI for mobile radios, FD-SOI for automotive and industrial computing, and increasingly Photonics-SOI for AI optical interconnects—competing on architecture-specific performance rather than commodity wafer volume. Fiscal 2026 revenue fell 34% to €591.8 million and the company swung to a €220 million net loss, yet Edge & Cloud AI revenue kept growing and the shares have since risen more than fivefold on AI-photonics enthusiasm, pushing trailing EV/sales to about 7.2x with an owner-earnings yield below the French government bond yield. Rating Watch: real technology and cash generation, but no margin of safety until shares fall back toward the €60-75 ideal buy zone.